Christiane Auray-Blais
Has grant
Full professor
CanadaResearch Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Christiane Auray-Blais is a Full Professor at Université de Sherbrooke, Canada. Her research primarily focuses on biomarker evaluation and metabolomics in lysosomal storage disorders, particularly Fabry and Gaucher diseases. Recent publications include studies on gene therapy responses, dietary impacts on vitamin B-12 status in older adults, and novel screening techniques for metabolic disorders utilizing mass spectrometry.
Recent Grants
Grant: Close
Evaluation of biomarkers for patients receiving Migalastat after switching from enzyme replacement therapy
Open Date: 2020-05-01
Close Date: 2023-04-01
Grant: Close
Biomarker evaluation in mouse tissues
Open Date: 2019-09-01
Close Date: 2020-09-01
Grant: Close
Batten disease (CLN2) biomarker discovery in urine and plasma using a mass spectrometry metabolomic approach
Open Date: 2019-01-01
Close Date: 2022-01-01
Grant: Close
Technological Upgrade for the Neonatal Urine Screening Program
Open Date: 2019-01-01
Close Date: 2021-01-01
Grant: Close
Biomarker Gb3 and lyso-Gb3 analysis from mice plasma and tissues from various organs using tandem mass spectrometry
Open Date: 2018-01-01
Close Date: 2018-12-01
Articles (13)
Year:
2024
Background: A biomarker profile was evaluated longitudinally in patients with Fabry disease switched from enzyme-replacement therapy (ERT) to migalastat. Methods: 16 Gb 3 isoforms and eight lyso-Gb 3 analogues were analyzed in plasma and urine by LC–MS/MS at baseline and at three different time points in naive participants and participants switching from either agalsidase α or β to migalastat. Results: 29 adult participants were recruited internationally (seven centers). The Mainz Severity Score Index and mean biomarker levels remained stable (p ≥ 0.05) over a minimum of 12 months compared with baseline following the treatment switch. Conclusion: In this cohort of patients with Fabry disease with amenable mutations, in the short term, a switch from ERT to migalastat did not have a marked effect on the average biomarker profile.
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Collaborators (3)
Pierrette GAUDREAU
Professor and researcher
Centre Hospitalier de l'Université de Montréal Centre de Recherche
michael west
Professor of Medicine
Dalhousie University
Daniel G Bichet
-
ApplyKite TwinLearns as you applyMake your next move.
Prepare your application
Review drafts before you send them.